Neuroendocrine bronchial and thymic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

The annual incidence of lung neuroendocrine tumour has been reported to be 1.35/100 000/year and the overall age adjusted incidence for thymic carcinoid 0.02/100 000/year. Of all neuroendocrine tumours, ∼25% are located in the respiratory tract. Both bronchial and thymic carcinoids may be part of mu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of oncology 2010-05, Vol.21 (suppl-5), p.v220-v222
Hauptverfasser: Öberg, K., Hellman, P., Kwekkeboom, D., Jelic, S.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The annual incidence of lung neuroendocrine tumour has been reported to be 1.35/100 000/year and the overall age adjusted incidence for thymic carcinoid 0.02/100 000/year. Of all neuroendocrine tumours, ∼25% are located in the respiratory tract. Both bronchial and thymic carcinoids may be part of multiple endocrine neoplasia type 1 syndrome (MEN-I) (5%–15%). The median age at diagnosis for lung neuroendocrine tumours is 64 years and for thymic tumours 59 years.
ISSN:0923-7534
1569-8041
1569-8041
DOI:10.1093/annonc/mdq191